ERBB2 and colorectal carcinoma: Some studies show no difference in survival between patients with HER2 positive and negative CRC, while others suggest an association between HER2 receptor overexpression and poorer three-year (70.8% vs. 83.7%) and five-year survival (55.1% vs. 78.3%, p < 0.05) [47].